ShelleyMShapiroMDPh.D
Cardiology • Los Angeles, CAAdult Congenital Heart Disease, Echocardiography, Heart Failure & Transplantation
Professor, Medicine, UCLA School of Medicine
Dr. Shapiro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Medical Plaza, Suite 365
Los Angeles, CA 90095Phone+1 310-825-8061Fax+1 310-825-8061
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1978 - 1981
Albert Einstein College of MedicineClass of 1978
Certifications & Licensure
CA State Medical License 1979 - 2027
NY State Medical License 2015 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
- Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension Start of enrollment: 2008 Jul 01
- Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Start of enrollment: 2009 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsTreatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities.R James White, Karim El-Kersh, Stephan Rosenkranz, Veronica Franco, Carmine Dario Vizza
Chest. 2024-11-30 - 1 citationsThe ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells.Michael I Lewis, Shelley Shapiro, Ronald J Oudiz, Mamoo Nakamura, Dael Geft
Ebiomedicine. 2024-02-01 - 2 citationsTyvaso DPI: Drug-device characteristics and patient clinical considerations.Colleen McEvoy, Rahul Argula, Sandeep Sahay, Shelley Shapiro, Christina Eagan
Pulmonary Pharmacology & Therapeutics. 2023-12-01
Press Mentions
United Therapeutics Announces FDA Approval of Tyvaso DPI™May 24th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
